Research Article
Shen Shouxiang, Li xia, Long S
Abstract
The aim of the study is to optimize the therapeutic dose and time window of picrosede II by orthogonal test in cerebral ischemic injury in rats . Methods, the forebrain ischemia models were established by bilateral common carotid artery occlusion (BCCAO) methods. The successful models were randomly divided into sixtee n groups according to orthogonal experimental design and intervened by injecting pic roside II intraperitonenally at different ischemic time with different dose. The concentratio ns of aquaporins 4 (AQP4), matrix metalloproteinases9 (MMP9) and cyclooxygenase 2 (CO X2) in serum were determined by enzyme linked immunosorbent assay to evaluate the t herapeutic effect of picroside II on cerebral ischemic injury. Results, the best therape utic time window and dose of picroside II in cerebral ischemic injury were (1) ischemia 2.0h wit h 20mg/kg body weight according to the concentration of AQP4; (2) ischemia 1.5h with 20mg/ kg according to the concentrations of MMP9; and (3) ischemia 1.5h with 10 mg/kg according to the concentrations of COX2 in serum. Conclusion, from the principle of lowest therapeuti c dose with longest time window, the optimized therapeutic dose and time window is injec ting picroside II intraperitonenally with 10-20mg/kg body weight at ischemia 1.5-2.0h in cere bral ischemic injury.